CRANFORD, N.J., Oct. 27 /PRNewswire/ -- Alan L. Rubino, former Hoffmann-La Roche senior executive and former CEO of two emerging pharmaceutical companies, and Timothy G. Rothwell, former Chairman, CEO, and President of sanofi-aventis U.S., have collaborated to form New American Therapeutics, Inc.
Mr. Rubino will serve as CEO and President, while Mr. Rothwell will function as the company's Chairman. The company's key emphasis will be on establishing a general specialty pharmaceutical presence built around select physician specialties and associated patient therapeutic needs.
"The decision to start New American Therapeutics was driven by changing industry trends and market forces," said Mr. Rubino. "We saw an opportunity to create a new and agile business model that is flexible and versatile enough to navigate the challenges in today's dynamic environment. The industry experience and performance track records of our leaders, board members, and management team provide us with a keen understanding of what works and what doesn't."
New American Therapeutics is being funded through a partnership with Deerfield Management Company, L.P. Deerfield is a privately owned healthcare investment management firm that was founded in 1994 and is based in New York, N.Y. Piper Jaffray & Co. served as exclusive financial advisor to the company on its initial financing transaction.
On October 1, 2010, New American Therapeutics announced that it acquired all U.S. rights to manufacture, market and sell the topical antiviral drug Denavir® (www.denavir.com). A proven treatment for cold sores since 1996, Denavir is the first product the company will be marketing and distributing.
"This was an opportunistic acquisition for us that met very specific criteria," explained Mr. Rubino. "It is an excellent therapeutic agent that, despite not receiving an adequate marketing investment, was still maintaining nearly a 50% prescription share of the topical antiviral market. That speaks volumes about physician and patient satisfaction."
Because of its current level of use in the marketplace coupled with a renewed commercial effort, Denavir is expected to provide a solid financial foundation for New American Therapeutics and will serve as the company's initial anchor product.
Beyond Denavir, New American Therapeutics will be pursuing marketed and launched assets that will benefit from the company's commercialization model. "Our progressive business strategy is already in the execution phase," said Mr. Rubino. "We will be tapping into our deep relationships within many U.S. and international pharmaceutical companies to explore product acquisition opportunities and other collaborations. We intend to move quickly and bring in products at a steady rate, which will allow us to grow in a rapid, yet calculated manner."
For more information about New American Therapeutics, visit www.natxcorp.com or call 908-282-7441.
About New American Therapeutics, Inc.
New American Therapeutics, Inc. is a privately held general specialty pharmaceutical company based in Cranford, N.J. that acquires, markets and distributes products that have the potential to improve outcomes for patients and provide more treatment options for physicians.
SOURCE New American Therapeutics, Inc.